The Rapidly Shifting Ketamine Landscape in the US – PMC

In recent years, ketamine has been hailed as a miracle treatment for depression and related disorders. The US Food and Drug Administration (FDA) approved the S-enantiomer of ketamine, esketamine, as the first antidepressant in a new class for treatment-resistant depression in 2019. 1 Emerging evidence suggests that the landscape of ketamine both as a medical therapeutic and as a recreational …

https://pmc.ncbi.nlm.nih.gov/articles/PMC12082568/